Mercedes-Benz Joins The Climate Pledge and Delivers More Than 1,800 Electric Vehicles to Amazon’s Delivery Fleet in Europe
Today, Amazon (NASDAQ: AMZN) announced it is adding more than 1,800 electric vehicles from Mercedes-Benz Vans to its delivery fleet in Europe this year. Amazon and Mercedes-Benz share a commitment to reduce emissions from the transportation sector, and Mercedes-Benz also announced today it has joined The Climate Pledge, which calls on signatories to be net zero carbon across their businesses by 2040—a decade ahead of the Paris Agreement goal of 2050.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200828005049/en/
Electric vehicle (Photo: Business Wire)
“We welcome the bold leadership demonstrated by Mercedes-Benz by signing up to The Climate Pledge and committing to ambitious action to address climate change. We need continued innovation and partnership from auto manufacturers like Mercedes-Benz to decarbonize the transportation sector and tackle the climate crisis,” said Jeff Bezos, Amazon founder and CEO. “Amazon is adding 1,800 electric delivery vehicles from Mercedes-Benz as part of our journey to build the most sustainable transportation fleet in the world, and we will be moving fast to get these vans on the road this year.”
“At Mercedes-Benz, we have set ourselves the ambitious target to make the transformation of mobility a success story. By joining ‘The Climate Pledge’ we are building on our goal to consistently pursue emission-free mobility and sustainable vehicle production,” said Ola Källenius, Chairman of the Board of Management of Daimler AG and Mercedes-Benz AG. “We stand with Amazon, Global Optimism and the other signatories of The Climate Pledge, in a commitment to being net zero carbon by 2040 – ten years ahead of The Paris Agreement. I am pleased that we will be able to gain even more momentum on our sustainability offensive with this step.”
As part of Mercedes-Benz’s commitment as the latest signatory of The Climate Pledge, the company is doubling down on its commitment to "Ambition2039," a roadmap to CO2-neutral mobility. The company is evaluating ways to remove carbon from its entire value chain, from development to the supplier network, from its own production to the electrification of products and beyond, as well as to ensuring renewable energies for the use phase of electric vehicles. With its goal to have a CO2-neutral fleet of new cars in less than 20 years, Mercedes-Benz is making an important contribution to slowing climate change. The company is already making good progress in this direction: By the end of this year, the vehicle portfolio will comprise five fully electric models and more than 20 plug-in hybrids. Signatories to The Climate Pledge also have the opportunity to share access to technologies, best practices and innovations in supply chain enhancements. They are also able to co-invest in new technologies and emerging solutions.
Amazon’s Delivery Service Partners will have access to the new fleet of zero-emission vehicles to make deliveries to customers in Europe this year, helping to save thousands of metric tons of carbon. The order is a milestone for Mercedes-Benz Vans, marking the largest order of electric vehicles for the manufacturer to date, and makes Amazon its largest sustainable transportation partner worldwide. More than 1,200 EVs in the order will be comprised of the newest electric commercial van available at Mercedes-Benz – the eSprinter, a larger model than the manufacturer’s first zero-emission vehicle, the eVito. The eSprinter includes state-of-the-art safety features including, electrical parking brake, active brake assist, reverse camera, blind spot assist, and more. The remaining 600 vehicles will be comprised of the manufacturer’s midsize electric van, the eVito, to give Delivery Service Partners operating in geographies that require a smaller-format vehicle access to a zero-emissions delivery option.
"I am delighted that we are further intensifying our long-standing partnership with Amazon and working together on the battery-electric future of transportation," said Marcus Breitschwerdt, Head of Mercedes-Benz Vans. “With the eVito and the eSprinter, we have electric vehicles in our portfolio, which are ideally suited for the requirements of the courier-, express- and parcel-service industry for goods delivery on the so-called ‘last mile’ in terms of their equipment and range. They show that local emission-free driving, convincing performance, comfort and low operating costs can be combined perfectly.”
“Amazon’s investment is a strong and concrete sign of its commitment and alignment to EU priorities,” said Fabio Massimo Castaldo, Vice President at the European Parliament. “Amazon continues to contribute to the achievement of the EU Green Deal goals, foster technological innovation and generate resilient and sustainable jobs in Europe. I hope that other corporations will follow Amazon’s example in the near future.”
Amazon is also committed to powering its growing electric fleet with clean energy. As part of The Climate Pledge, Amazon is investing in renewable energy as a critical step toward addressing our carbon footprint globally and has committed to run on 100% renewable energy by 2025. Globally, Amazon has 91 renewable energy projects that have the capacity to generate over 2,900 MW and deliver more than 7.5 million MWh of energy annually. These projects include 31 utility-scale wind and solar renewable energy projects and 60 solar rooftops on fulfillment centers and sort centers around the globe.
About Amazon
Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. Customer reviews, 1-Click shopping, personalized recommendations, Prime Fulfillment by Amazon, AWS, Kindle Direct Publishing, Kindle, Fire tablets, Fire TV, Amazon Echo, and Alexa are some of the products and services pioneered by Amazon. For more information, visit www.amazon.com/about and follow @AmazonNews.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200828005049/en/
Contact information
Amazon.com, Inc.
Media Hotline
Amazon-pr@amazon.com
www.amazon.com/pr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Curing the Incurable with ‘Biological Age Zero’ Cells: Clonell™ Launches the Ultimate Regenerative Medicine Platform5.1.2026 15:00:00 EET | Press release
Clonell Therapeutics, Inc., a leading biotechnology company dedicated to curing intractable and incurable diseases, announced today the official launch of the world's first 'Patient-Specific Embryonic Stem Cell (Somatic Cell Nuclear Transfer-derived Embryonic Stem Cell, hereinafter SCNT-ESC)' therapy platform based on Somatic Cell Nuclear Transfer (SCNT) technology. Concurrently, the company has initiated its innovative 'Patient-Initiated Clinical Trial™' to apply this breakthrough technology directly to patients. This platform launch is evaluated as presenting the true 'Gold Standard' in regenerative medicine by perfectly resolving the inherent challenges—such as immune rejection, incomplete reprogramming, and the inheritance of aging—that have been cited as limitations of existing stem cell therapies. Clonell's SCNT technology establishes a patient-specific embryonic stem cell line by transferring the nucleus of a patient's somatic cell into a healthy enucleated oocyte. This process
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi ® /Minjuvi ® ) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 14:30:00 EET | Press release
Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years of age, or age-adjusted IPI (aaIPI) of two to three (2-3) for patients ≤60 years of age. The trial met its primary endpoint of progression-free survival (PFS) by investigator assessment (Hazard Ratio 0.75 [0.59,0.96]; p-value 0.019), according to Lugano 2014 criteria. The trial also met its key secondary endpoint of event-free survival (EFS) by investigator assessment. No new safety signals were observed. “The frontMIND stud
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 14:30:00 EET | Press release
Cybin Inc. (the “Company”) doing business as Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (“Helus Pharma”), a clinical stage pharmaceutical company committed to helping minds heal by developing NSAs, today announced that the Company will operate under the business name Helus Pharma (pronounced “Heal-Us”) and trade on Nasdaq with ticker symbol HELP. “Our new business name more accurately describes our compounds and reflects our anticipated transformation from a global clinical stage discovery and development company to a commercial-ready pharmaceutical company, with our two lead candidates HLP003 and HLP004,” said Eric So, interim chief executive officer of the Company. “Over the past several years, we have advanced our pipeline portfolio of differentiated, proprietary NSA drug candidates, which includes over 350 filed patents with more than 100 already granted. We are approaching the commercialization of HLP003 with strong clinical data and significant market potential, subject to the
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)5.1.2026 14:00:00 EET | Press release
Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell production to control hematocrit levels in patients with PV. “This is an important milestone toward our goal of addressing critical gaps that patients living with polycythemia vera face today,” said Teresa Bitetti, President, Global Oncology Business Unit, Takeda. “The comprehensive VERIFY study data underscore rusfertide’s strong clinical profile and potential to provide sustained hematocrit control while reducing phlebotomy and symptom burden. Our collaboration with Protagonist exemplifies how partnerships can advance innovative science, with a focus on m
SBC Medical Accelerates Global Expansion with Strategic Investment and Alliance with a Leading U.S. MedSpa Platform OrangeTwist as Part of Broader Growth Strategy5.1.2026 14:00:00 EET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210926005/en/ OrangeTwist Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom